Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.

Eva-Maria Fuchs, Wolfgang J. Köstler, Reinhard Horvat, Gernot Hudelist, Ernst Kubista, Johannes Attems, Christoph C. Zielinski, Christian F. Singer, High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting. International Journal of Cancer. ,vol. 135, pp. 224- 231 ,(2014) , 10.1002/IJC.28660

Silvia Boero, Anna Morabito, Barbara Banelli, Barbara Cardinali, Beatrice Dozin, Gianluigi Lunardi, Patrizia Piccioli, Sonia Lastraioli, Roberta Carosio, Sandra Salvi, Alessia Levaggi, Francesca Poggio, Alessia D’Alonzo, Massimo Romani, Lucia Del Mastro, Alessandro Poggi, Maria Pia Pistillo, Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines Journal of Translational Medicine. ,vol. 13, pp. 324- 324 ,(2015) , 10.1186/S12967-015-0680-0

A Borley, T Mercer, M Morgan, P Dutton, P Barrett-Lee, M Brunelli, B Jasani, Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network British Journal of Cancer. ,vol. 110, pp. 2139- 2143 ,(2014) , 10.1038/BJC.2014.147

Aman U. Buzdar, Vicente Valero, Nuhad K. Ibrahim, Deborah Francis, Kristine R. Broglio, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, Sonja E. Singletary, Kelly K. Hunt, Aysegul A. Sahin, Francisco Esteva, William F. Symmans, Michael S. Ewer, Thomas A. Buchholz, Gabriel N. Hortobagyi, Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen Clinical Cancer Research. ,vol. 13, pp. 228- 233 ,(2007) , 10.1158/1078-0432.CCR-06-1345

Edith A Perez, Edward H Romond, Vera J Suman, Jong-Hyeon Jeong, George Sledge, Charles E Geyer Jr, Silvana Martino, Priya Rastogi, Julie Gralow, Sandra M Swain, Eric P Winer, Gerardo Colon-Otero, Nancy E Davidson, Eleftherios Mamounas, Jo Anne Zujewski, Norman Wolmark, None, Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Journal of Clinical Oncology. ,vol. 32, pp. 3744- 3752 ,(2014) , 10.1200/JCO.2014.55.5730

Ji-Won Kim, Jee Hyun Kim, Seock-Ah Im, Yu Jung Kim, Hye-Suk Han, Jin-Soo Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Yoon Kyung Jeon, Do-Youn Oh, Tae-You Kim, In Ae Park, HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer Cancer Chemotherapy and Pharmacology. ,vol. 72, pp. 109- 115 ,(2013) , 10.1007/S00280-013-2174-1

Qijia Xuan, Hongfei Ji, Xuanchen Tao, Yongpeng Xu, Qingyuan Zhang, Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes Breast Cancer Research and Treatment. ,vol. 150, pp. 581- 588 ,(2015) , 10.1007/S10549-015-3334-2

Giuseppe Gullo, Daniela Bettio, Valter Torri, Giovanna Masci, Piermario Salvini, Armando Santoro, Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer Investigational New Drugs. ,vol. 27, pp. 179- 183 ,(2009) , 10.1007/S10637-008-9155-Y

S Guiu, M Gauthier, B Coudert, F Bonnetain, L Favier, S Ladoire, H Tixier, B Guiu, F Penault-Llorca, F Ettore, P Fumoleau, L Arnould, Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer British Journal of Cancer. ,vol. 103, pp. 1335- 1342 ,(2010) , 10.1038/SJ.BJC.6605939

Kunpeng Wu, Qiaozhu Yang, Yi Liu, Aibing Wu, Zhixiong Yang, Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy World Journal of Surgical Oncology. ,vol. 12, pp. 95- 95 ,(2014) , 10.1186/1477-7819-12-95